![EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/deadb8b4-db2c-4e44-bffc-db9fd3c5a015/gr1.jpg)
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology
![ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) LAUNCHED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA | News Release:2021 | Eisai Co., Ltd. ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) LAUNCHED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA | News Release:2021 | Eisai Co., Ltd.](https://www.eisai.com/news/2021/images/202169-1.png)
ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) LAUNCHED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA | News Release:2021 | Eisai Co., Ltd.
![ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer](https://www.urotoday.com/images/com-doc-importer/16-esmo-2021/esmo-2021-586p-safety-of-tazemetostat-taz-in-combination-with-abiraterone-prednisone-a-p-or-enzalutamide-e-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc/image-0.jpg)
ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
![Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/39a0389e-5255-43d9-8651-1121f88882df/gr2.jpg)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology
![Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma](https://oncpracticemanagement.com/images/Tables-Figures/2021/04/OPM-2021-04-JCode-Pg21-Tbl-Tazemetostat-Efficacy.png)
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
![Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study - The Lancet Oncology Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/3447e2d9-9832-4957-a48d-f02c7b6e7724/gr1_lrg.jpg)
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study - The Lancet Oncology
![Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer](https://pub.mdpi-res.com/cancers/cancers-15-01569/article_deploy/html/images/cancers-15-01569-g001.png?1677817327)
Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and Evolution Prospects | Journal of Medicinal Chemistry
![Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire](https://mms.businesswire.com/media/20180924005110/en/675037/23/Epizyme-Logo-Trademark.jpg)
Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire
![Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/1d999e19-e581-453a-a14a-6322f3d076dc/gr1.jpg)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology
OncLive.com on Twitter: "Watch our upcoming live broadcast reviewing a new indication, clinical trial data, and dosing for TAZVERIK TM (tazemetostat): https://t.co/YKnSN20tj9 https://t.co/ZfU6XQc4Gd" / Twitter
![Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2119213479/2090684048/gr1.jpg)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology
![Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A](https://ars.els-cdn.com/content/image/1-s2.0-S0006497118712536-gr1.jpg)
Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A
![The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment - Yuan - 2021 - Cancer Science - Wiley Online Library The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment - Yuan - 2021 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/84af5301-a0b9-4870-98f1-a796851460e5/cas15122-fig-0001-m.jpg)